Vical (Nasdaq: VICL) 45.6% LOWER; announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE